Neuroinflammation is increasingly recognized as central to AD pathogenesis, with emerging therapies targeting this mechanism. Yet, given the novelty and rapid evolution of data, neurology and psychiatry providers lack familiarity with these advances. 

A total of 1400 neurology or psychiatry providers managing patients with AD participated. At baseline, 33% lacked knowledge regarding the role of neuroinflammation in AD, and 35% were unfamiliar with biomarkers for early detection, while 59% and 35% were uninformed regarding donanemab and semaglutide, respectively. Among those who answered correctly, confidence was low - only 14% were correct and confident regarding neuroinflammation and biomarkers, 5% for donanemab, and 4% for semaglutide. This lack of knowledge and confidence translated into gaps in comfortability, with only 43% understanding the link between neuroinflammation and AD and even fewer (15%) familiar with emerging agents. Post-education, mastery of topics (high confidence and correct) increased substantially, including 4.35-fold for neuroinflammation, 3.35-fold for biomarkers, and 7.25-fold for semaglutide, though gains for donanemab were minimal (1.4-fold). This led to 67% of providers planning to incorporate clinical evidence into decision-making, with nearly half expressing high confidence doing so.